Chemistry

#AI / data analytics / healthtech / informatics #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Patent Law #PCR #Precision medicine #RNA #Screening #Target validation #Therapeutics #Toxicology

Automated Liquid Handler Vendor vs Third Party Plastic Company

Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a 'compatible' product from a third party plastics… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Organic chemistry #Orphan drugs #Pathology #Pharmacogenomics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Business #Cell culture #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Is The Cloud Enabling Bioinformatics to Become the Biology Solutions Domain?

By Dr Paul Denny-Gouldson For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that have been labelled as such… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Preclinical #Regulatory #RNA #Screening #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Filling the drug discovery abyss

Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Lead discovery #Medicinal chemistry #Precision medicine #Preclinical #RNA #Target validation #Toxicology

Why Adopting AI is Essential for a Sustainable Pharma Industry

Why Adopting AI is Essential for a Sustainable Pharma Industry By Professor Jackie Hunter Advancements in technology, and in particular, developments in artificial intelligence (AI) are revolutionising the way that we live our lives. Up to now, we have used it to help us find the quickest route home or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Genetics #High Content Screening #High throughput screening #Imaging #Immunology #Medicinal chemistry #Microfluidics #Molecular medicine #Oncology #Organic chemistry #Pathology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Cellular Imaging – Advances and Considerations for High-Content Screening

3D Cellular Imaging - Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

I Robot. I, The Future – Robotics Within and Beyond The Lab

I Robot. I, The Future - Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Ion Channels – Increasingly Enticing Targets For Drug Discovery

Ion Channels - Increasingly Enticing Targets For Drug Discovery by Dr Douglas Krafte and Deborah Erickson Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease. Pfizer Inc’s… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Metabolomics #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Translational #Translational chemistry

Epigenetic Modulators of Histone Methylation

Epigenetic Modulators of Histone Methylation By Dr Michael Thomenius and William P. Janzen Drug Discovery Epigenetics is a term that refers to the durable and context-specific regulation of transcription processes. The majority of epigenetics involves a complex system of enzymes, binding proteins and accessory proteins that control access to the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microbiology #Microbiome #Molecular medicine #Oncology #Pathology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Metabolomics – A Playbook for Functional Genomics

Metabolomics - A Playbook for Functional Genomics By Dr David Ferrick If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily… Read More

#Archive

High content screening
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Latest Developments in High Content Screening Systems

By Dr John Comley High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, high content imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Metabolomics #Microbiome #Organic chemistry #Protein chemistry / Proteomics #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

With Synthetic Biology, Drug Discovery Is Going Virtual

With Synthetic Biology, Drug Discovery Is Going Virtual by Christopher Voigt Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and applying synthetic… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Oncology #Pathology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Coming Age Of Mass Spectrometry Imaging

The Coming Age Of Mass Spectrometry Imaging By Dr Peter J.H. Webborn and Dr Richard J.A. Goodwin Mapping complex drug distribution/retention in tissues, aligned with efficacy and safety biomarker localisation is now possible using label-free mass spectrometry imaging technologies. While there remain challenges to be overcome, these molecular imaging techniques… Read More

#Archive

Stem cells
#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biobanking #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The stem cell dilemma: Reprogramming in-house versus off-the-shelf

  by Dr John Comley The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted. Human induced pluripotent stem cells (iPSCs) are seen as a resource from which to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Molecular medicine #Orphan drugs #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Drug Discovery in a Multi-Omics World

Drug Discovery in a Multi-Omics World By Mike Furness Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development. This… Read More

#Archive